Risk of post-procedural bleeding in children on intravenous fish oil.

Autor: Nandivada P; Vascular Biology Program and the Department of Surgery, Boston Children's Hospital, Boston, MA, USA., Anez-Bustillos L; Vascular Biology Program and the Department of Surgery, Boston Children's Hospital, Boston, MA, USA., O'Loughlin AA; Vascular Biology Program and the Department of Surgery, Boston Children's Hospital, Boston, MA, USA., Mitchell PD; Clinical Research Center, Biostatistics Core, Boston Children's Hospital, Boston, MA, USA., Baker MA; Vascular Biology Program and the Department of Surgery, Boston Children's Hospital, Boston, MA, USA., Dao DT; Vascular Biology Program and the Department of Surgery, Boston Children's Hospital, Boston, MA, USA., Fell GL; Vascular Biology Program and the Department of Surgery, Boston Children's Hospital, Boston, MA, USA., Potemkin AK; Vascular Biology Program and the Department of Surgery, Boston Children's Hospital, Boston, MA, USA., Gura KM; Department of Pharmacy, Boston Children's Hospital, Boston, MA, USA., Neufeld EJ; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA., Puder M; Vascular Biology Program and the Department of Surgery, Boston Children's Hospital, Boston, MA, USA. Electronic address: mark.puder@childrens.harvard.edu.
Jazyk: angličtina
Zdroj: American journal of surgery [Am J Surg] 2017 Oct; Vol. 214 (4), pp. 733-737. Date of Electronic Publication: 2016 Dec 01.
DOI: 10.1016/j.amjsurg.2016.10.026
Abstrakt: Background: Intestinal failure-associated liver disease (IFALD) can be treated with parenteral fish oil (FO) monotherapy, but practitioners have raised concerns about a potential bleeding risk. This study aims to describe the incidence of clinically significant post-procedural bleeding (CSPPB) in children receiving FO monotherapy.
Methods: A retrospective chart review was performed on patients at our institution treated with intravenous FO for IFALD. CSPPB was defined as bleeding leading to re-operation, transfer to the intensive care unit, re-admission, or death, up to one month after any invasive procedure.
Results: From 244 patients reviewed, 183 underwent ≥1 invasive procedure(s) (n = 732). Five (0.68%, 95% CI 0.22-1.59%) procedures resulted in CSPPB. FO therapy was never interrupted. No deaths due to bleeding occurred.
Conclusions: Findings suggest that FO therapy is safe, with a CSPPB risk no greater than that reported in the general population. O3FA should not be held in preparation for procedures or in the event of bleeding.
(Copyright © 2016 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: